SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 5768.
  • 2
    Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. Blood 2008; 111: 55155523.
  • 3
    Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective dutch childhood oncology group (DCOG) protocol ALL-9(1997–2004). Lancet Oncol 2009; 10: 957966.
  • 4
    Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 27302741.
  • 5
    Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL collaborative group overview of 43 randomized trials. J Clin Oncol 2003; 21: 17981809.
  • 6
    Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the children's cancer group. Blood 2003; 101: 38093817.
  • 7
    Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005; 129: 734745.
  • 8
    Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol 2010; 11: 10961106.
  • 9
    Escherich G, Richards S, Stork LC, et al. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia 2011; 25: 953959.
  • 10
    Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer. Volume 1: Worldwide Evidence 1985–1990. Oxford, UK: Oxford University Press; 1990. 207 pp.
  • 11
    Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: Results of the children's cancer group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the children's oncology group. Blood 2006; 108: 11651173.
  • 12
    Littman P, Coccia P, Bleyer WA, et al. Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). Int J Radiat Oncol Biol Phys 1987; 13: 14431449.
  • 13
    Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A childrens cancer group report. J Clin Oncol 1993; 11: 520526.
  • 14
    Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the children's cancer group. J Clin Oncol 1998; 16: 920930.
  • 15
    van Eys J, Berry D, Crist W, et al. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study. Cancer 1989; 63: 2329.
  • 16
    Ortega JJ, Javier G, Olive T. Treatment of standard- and high-risk childhood acute lymphoblastic leukaemia with two CNS prophylaxis regimens. Haematol Blood Transfus 1987; 30: 483492.
  • 17
    Stark B, Nirel R, Avrahami G, et al. Long-term results of the Israeli national studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 2010; 24: 419424.
  • 18
    Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana–Farber cancer institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896904.
  • 19
    Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996; 97: 7380.
  • 20
    Mahoney DHJ, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy—A pediatric oncology group study. J Clin Oncol 1998; 16: 17121722.
  • 21
    Schaison GS, Baruchel A, Leblanc TAM, et al. Therapy of childhood acute lymphoblastic leukemia. Int J Pediatr Hematol Oncol 1998; 5: 145154.
  • 22
    Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of total therapy study XIIIB at St. Jude children's research hospital. Blood 2004; 104: 26902696.
  • 23
    Lange BJ, Blatt J, Sather HN, et al. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A childrens cancer group study. Med Pediatr Oncol 1996; 27: 1520.
  • 24
    LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana–Farber ALL consortium protocol 87-01. J Clin Oncol 2002; 20: 237246.
  • 25
    Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124: 3346.
  • 26
    Niemeyer CM, Reiter A, Riehm H, et al. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin–Frankfurt–Munster and Dana–Farber cancer institute protocols. Ann Oncol 1991; 2: 745749.
  • 27
    Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: A randomized study by the children's oncology group (POG 9404). Blood 2011; 118: 874883.
  • 28
    Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A pediatric oncology group study. J Clin Oncol 1993; 11: 839849.
  • 29
    Henderson ES, Scharlau C, Cooper MR, et al. Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: Results of CALGB protocol 7113. Leuk Res 1979; 3: 395407.
  • 30
    Bleyer WA. Intrathecal methotrexate versus central nervous system leukemia. Cancer Drug Deliv 1984; 1: 157167.
  • 31
    Medical Research Council leukaemia trial, UKALL VII. A report to the Council by the Working Party on Leukaemia in Childhood Arch Dis Child 1985; 60: 10501054.
  • 32
    Freeman AI, Boyett JM, Glicksman AS, et al. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: A ten-year follow-up. Med Pediatr Oncol 1997; 28: 98107.
  • 33
    Poplack DG, Reaman GH, Bleyer WA, et al. CNS preventive therapy with high-dose methotrexate in acute lymphoblastic leukemia: A preliminary report. Proc Am Soc Clin Oncol 1984; 3: abstr 797.
  • 34
    Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265284.
  • 35
    Zintl F, Plenert W, Malke H. Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German democratic republic. Haematol Blood Transfus 1987; 30: 471479.
  • 36
    Tsurusawa M, Katano N, Yamamoto Y, et al. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: Report from the Japanese children's cancer and leukemia study group. Med Pediatr Oncol 1999; 32: 259266.
  • 37
    Viana MB, Murao M, Ramos G, et al. Malnutrition as a prognostic factor in lymphoblastic leukaemia: A multivariate analysis. Arch Dis Child 1994; 71: 304310.
  • 38
    Tsuchida M, Ohara A, Manabe A, et al. Long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984–1999. Leukemia 2010; 24: 383396.
  • 39
    Hann I, Vora A, Richards S, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials. UK medical research council's working party on childhood leukaemia. Leukemia 2000; 14: 356363.
  • 40
    Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: A report from the children's oncology group. Leukemia 2010; 24: 355370.
  • 41
    Chessells JM, Durrant J, Hardy RM, et al. Medical research council leukaemia trial–UKALL V: An attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the council by the working party on leukaemia in childhood. J Clin Oncol 1986; 4: 17581764.
  • 42
    Eden OB, Lilleyman JS, Richards S. Testicular irradiation in childhood lymphoblastic leukaemia. Medical research council working party on leukemia in childhoods. Br J Haematol 1990; 75: 496498.
  • 43
    Brandalise S, Odone V, Pereira W, et al. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian group. Leukemia 1993; 7: S142S145.
  • 44
    Tsuchida M, Akatsuka J, Bessho F, et al. Treatment of acute lymphoblastic leukemia in the Tokyo children's cancer study group—Preliminary results of L84-11 protocol. Acta Paediatr Jpn 1991; 33: 522532.
  • 45
    Duttera MJ, Bleyer WA, Pomeroy TC, et al. Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet 1973; 2: 703707.
  • 46
    Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991; 19: 269275.
  • 47
    Komp DM, Fernandez CH, Falletta JM, et al. CNS prophylaxis in acute lymphoblastic leukemia: Comparison of two methods a Southwest oncology group study. Cancer 1982; 50: 10311036.
  • 48
    Dritschilo A, Cassady JR, Camitta B, et al. The role of irradiation in central nervous system treatment and prophylaxis for acute lymphoblastic leukemia. Cancer 1976; 37: 27292735.
  • 49
    Brecher ML, Berger P, Freeman AI, et al. Computerized tomography scan findings in children with acute lymphocytic leukemia treated with three different methods of central nervous system prophylaxis. Cancer 1985; 56: 24302433.
  • 50
    Ortega JA, Nesbit ME, Sather HN, et al. Long-term evaluation of a CNS prophylaxis trial–treatment comparisons and outcome after CNS relapse in childhood ALL: A report from the childrens cancer study group. J Clin Oncol 1987; 5: 16461654.
  • 51
    Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the children's cancer group. Cancer 1998; 82: 600612.
  • 52
    Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. children leukemia cooperative group. Leukemia 2000; 14: 22572266.
  • 53
    Donadieu J, Auclerc MF, Baruchel A, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: Differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French acute lymphoblastic leukaemia study group. Br J Haematol 1998; 102: 729739.
  • 54
    Holland JF, Glidewell O. Chemotherapy of acute lymphocytic leukemia of childhood. Cancer 1972; 30: 14801487.
  • 55
    Sackmann Muriel F, Pavlovsky S, Penalver JA, et al. Evaluation of induction of remission, intensification, and central nervous system prophylactic treatment in acute lymphoblastic leukemia. Cancer 1974; 34: 418426.
  • 56
    Moss HA, Nannis ED, Poplack DG. The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. Am J Med 1981; 71: 4752.
  • 57
    Borsi JD, Wesenberg F, Stokland T, et al. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia. Eur J Cancer 1991; 27: 10061009.
  • 58
    Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20: 19551962.
  • 59
    Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the children's oncology group. Blood 2011; 118: 243251.
  • 60
    Winick NJ, Salzer WL, Devidas M, et al. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the children's onocology group study AALL0232. J Clin Oncol 2011; 29: abstr 9504.
  • 61
    Larsen EC, Salzer WL, Devidas M, et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginse (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the children's oncology group study AALL0232. J Clin Oncol 2011; 29: abstr 3.
  • 62
    Nathan PC, Whitcomb T, Wolters PL, et al. Very high-dose methotrexate (33.6g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: Results of national cancer institute/children's cancer group trials CCG-191P, CCG-134P and CCG-144P. Leuk Lymphoma 2006; 47: 24882504.